What contributes more strongly to predicting QOL during 1-year recovery from treatment for clinically localized prostate cancer: 4-Weeks-post-treatment depressive symptoms or type of treatment?

Patrick Monahan, Victoria Champion, Susan Rawl, R. Brian Giesler, Barbara Given, Charles W. Given, Debra Burns, Silvia Bigatti, Kristina M. Reuille, Faouzi Azzouz, Jingwei Wu, Michael Koch

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: Research on prostate cancer and quality of life (QOL) has focused on the effects of treatment type on subsequent QOL, without considering effects of depressive symptoms. The present purpose is to test the independent contribution of depressive symptoms (measured within 4 weeks after treatment) and treatment type in predicting QOL measured 4, 7, and 12 months following treatment for clinically localized prostate cancer. Methods: The 105 patients (all Stage I-II) were newly treated with radical prostatectomy, external beam radiation (EBR) or brachytherapy. Age ranged from 42 to 80 (mean = 64); 88% Caucasian and 9% African American. Repeated measures mixed linear models were adjusted for age, race, education, and marital status. Results: Depressive symptoms significantly (p < 0.01) predicted 8 of 10 disease-specific and 7 of 7 generic QOL outcomes. Treatment type significantly (p < 0.01) predicted urinary function and bowel bother but no generic QOL outcomes. Conclusions: Depressive symptoms appears to predict a wider range of QOL outcomes (measured 4-12 months after treatment) than treatment type; however, when treatment is significant its effect sizes are slightly larger than depressive symptoms. Health care providers should (1) assess depressive symptoms in prostate cancer patients before and after treatment, and (2) provide psychosocial (e.g., counseling, support groups) and pharmacologic treatment options for improving depressive symptoms.

Original languageEnglish
Pages (from-to)399-411
Number of pages13
JournalQuality of Life Research
Volume16
Issue number3
DOIs
StatePublished - Apr 2007

Fingerprint

Prostatic Neoplasms
Quality of Life
Depression
Therapeutics
Self-Help Groups
Brachytherapy
Marital Status
Prostatectomy
African Americans
Health Personnel
Counseling
Linear Models
Radiation
Education
Research

Keywords

  • Depression
  • Depressive symptoms
  • Prostate cancer
  • Quality of life
  • Treatment

ASJC Scopus subject areas

  • Rehabilitation
  • Nursing(all)

Cite this

What contributes more strongly to predicting QOL during 1-year recovery from treatment for clinically localized prostate cancer : 4-Weeks-post-treatment depressive symptoms or type of treatment? / Monahan, Patrick; Champion, Victoria; Rawl, Susan; Giesler, R. Brian; Given, Barbara; Given, Charles W.; Burns, Debra; Bigatti, Silvia; Reuille, Kristina M.; Azzouz, Faouzi; Wu, Jingwei; Koch, Michael.

In: Quality of Life Research, Vol. 16, No. 3, 04.2007, p. 399-411.

Research output: Contribution to journalArticle

@article{6beb923a77564389b16730a21eb6b562,
title = "What contributes more strongly to predicting QOL during 1-year recovery from treatment for clinically localized prostate cancer: 4-Weeks-post-treatment depressive symptoms or type of treatment?",
abstract = "Purpose: Research on prostate cancer and quality of life (QOL) has focused on the effects of treatment type on subsequent QOL, without considering effects of depressive symptoms. The present purpose is to test the independent contribution of depressive symptoms (measured within 4 weeks after treatment) and treatment type in predicting QOL measured 4, 7, and 12 months following treatment for clinically localized prostate cancer. Methods: The 105 patients (all Stage I-II) were newly treated with radical prostatectomy, external beam radiation (EBR) or brachytherapy. Age ranged from 42 to 80 (mean = 64); 88{\%} Caucasian and 9{\%} African American. Repeated measures mixed linear models were adjusted for age, race, education, and marital status. Results: Depressive symptoms significantly (p < 0.01) predicted 8 of 10 disease-specific and 7 of 7 generic QOL outcomes. Treatment type significantly (p < 0.01) predicted urinary function and bowel bother but no generic QOL outcomes. Conclusions: Depressive symptoms appears to predict a wider range of QOL outcomes (measured 4-12 months after treatment) than treatment type; however, when treatment is significant its effect sizes are slightly larger than depressive symptoms. Health care providers should (1) assess depressive symptoms in prostate cancer patients before and after treatment, and (2) provide psychosocial (e.g., counseling, support groups) and pharmacologic treatment options for improving depressive symptoms.",
keywords = "Depression, Depressive symptoms, Prostate cancer, Quality of life, Treatment",
author = "Patrick Monahan and Victoria Champion and Susan Rawl and Giesler, {R. Brian} and Barbara Given and Given, {Charles W.} and Debra Burns and Silvia Bigatti and Reuille, {Kristina M.} and Faouzi Azzouz and Jingwei Wu and Michael Koch",
year = "2007",
month = "4",
doi = "10.1007/s11136-006-9127-7",
language = "English",
volume = "16",
pages = "399--411",
journal = "Quality of Life Research",
issn = "0962-9343",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - What contributes more strongly to predicting QOL during 1-year recovery from treatment for clinically localized prostate cancer

T2 - 4-Weeks-post-treatment depressive symptoms or type of treatment?

AU - Monahan, Patrick

AU - Champion, Victoria

AU - Rawl, Susan

AU - Giesler, R. Brian

AU - Given, Barbara

AU - Given, Charles W.

AU - Burns, Debra

AU - Bigatti, Silvia

AU - Reuille, Kristina M.

AU - Azzouz, Faouzi

AU - Wu, Jingwei

AU - Koch, Michael

PY - 2007/4

Y1 - 2007/4

N2 - Purpose: Research on prostate cancer and quality of life (QOL) has focused on the effects of treatment type on subsequent QOL, without considering effects of depressive symptoms. The present purpose is to test the independent contribution of depressive symptoms (measured within 4 weeks after treatment) and treatment type in predicting QOL measured 4, 7, and 12 months following treatment for clinically localized prostate cancer. Methods: The 105 patients (all Stage I-II) were newly treated with radical prostatectomy, external beam radiation (EBR) or brachytherapy. Age ranged from 42 to 80 (mean = 64); 88% Caucasian and 9% African American. Repeated measures mixed linear models were adjusted for age, race, education, and marital status. Results: Depressive symptoms significantly (p < 0.01) predicted 8 of 10 disease-specific and 7 of 7 generic QOL outcomes. Treatment type significantly (p < 0.01) predicted urinary function and bowel bother but no generic QOL outcomes. Conclusions: Depressive symptoms appears to predict a wider range of QOL outcomes (measured 4-12 months after treatment) than treatment type; however, when treatment is significant its effect sizes are slightly larger than depressive symptoms. Health care providers should (1) assess depressive symptoms in prostate cancer patients before and after treatment, and (2) provide psychosocial (e.g., counseling, support groups) and pharmacologic treatment options for improving depressive symptoms.

AB - Purpose: Research on prostate cancer and quality of life (QOL) has focused on the effects of treatment type on subsequent QOL, without considering effects of depressive symptoms. The present purpose is to test the independent contribution of depressive symptoms (measured within 4 weeks after treatment) and treatment type in predicting QOL measured 4, 7, and 12 months following treatment for clinically localized prostate cancer. Methods: The 105 patients (all Stage I-II) were newly treated with radical prostatectomy, external beam radiation (EBR) or brachytherapy. Age ranged from 42 to 80 (mean = 64); 88% Caucasian and 9% African American. Repeated measures mixed linear models were adjusted for age, race, education, and marital status. Results: Depressive symptoms significantly (p < 0.01) predicted 8 of 10 disease-specific and 7 of 7 generic QOL outcomes. Treatment type significantly (p < 0.01) predicted urinary function and bowel bother but no generic QOL outcomes. Conclusions: Depressive symptoms appears to predict a wider range of QOL outcomes (measured 4-12 months after treatment) than treatment type; however, when treatment is significant its effect sizes are slightly larger than depressive symptoms. Health care providers should (1) assess depressive symptoms in prostate cancer patients before and after treatment, and (2) provide psychosocial (e.g., counseling, support groups) and pharmacologic treatment options for improving depressive symptoms.

KW - Depression

KW - Depressive symptoms

KW - Prostate cancer

KW - Quality of life

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=33847658392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847658392&partnerID=8YFLogxK

U2 - 10.1007/s11136-006-9127-7

DO - 10.1007/s11136-006-9127-7

M3 - Article

C2 - 17091363

AN - SCOPUS:33847658392

VL - 16

SP - 399

EP - 411

JO - Quality of Life Research

JF - Quality of Life Research

SN - 0962-9343

IS - 3

ER -